2002 til et usædvanligt år i agenturets historie, idet det var det laveste antal nye ansøgninger, siden EMEA indledte sin virksomhed i 1995.
As an organisation, the impact of this on the EMEA was particularly felt since the Agency is heavily dependent on revenue of fees paid by the pharmaceutical industry in its budget.